Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120676861> ?p ?o ?g. }
- W2120676861 endingPage "724" @default.
- W2120676861 startingPage "719" @default.
- W2120676861 abstract "Despite the availability of several therapeutic options for metastatic breast cancer (MBC), no robust predictive factors are available to help clinical decision making. Nevertheless, a decreasing benefit from first line to subsequent lines of treatment is commonly observed. The aim of this study was to assess the impact of benefit from first-line therapy on outcome with subsequent lines.We analyzed a consecutive series of 472 MBC patients treated with chemotherapy (CT) and/or endocrine therapy (ET) between 2004 and 2012. We evaluated progression-free survival (PFS) at first (PFS1), second, third, and fourth therapeutic lines, according to treatment (ET and/or CT) and tumor subtypes.In the whole cohort, median overall survival was 34 months, and median PFS1 was 9 months. A 6-month benefit was shown by 289 patients (63.5%) at first line, 128 (40.5%) at second line, 76 (33.8%) at third line, and 34 (23.3%) at fourth line. Not having a 6-month benefit at PFS1 was associated with less chance of benefit at second line (odds ratio [OR]: 0.48; 95% confidence interval [CI]: 0.29-0.77, p = .0026) and at any line beyond first (OR: 0.39; 95% CI: 0.24-0.62, p < .0001). In the total series, after stratification for tumor subtypes, a strong predictive effect was observed among HER2-positive tumors (OR: 0.2; 95% CI: 0.05-0.73, p = .0152).Our results suggest that the absence of at least a 6-month benefit in terms of PFS with first-line therapy predicts a reduced probability of benefit from subsequent therapeutic lines, especially in HER2-positive disease.This study supports evidence showing that the absence of a 6-month benefit in terms of progression-free survival with first-line therapy predicts a lack of benefit from subsequent therapeutic lines in metastatic breast cancer. The random distribution of benefit experienced by a subset of the cohort further spurs an interest in identifying predictive factors capable of identifying the most appropriate therapeutic strategy." @default.
- W2120676861 created "2016-06-24" @default.
- W2120676861 creator A5008925729 @default.
- W2120676861 creator A5009976972 @default.
- W2120676861 creator A5023227998 @default.
- W2120676861 creator A5037725332 @default.
- W2120676861 creator A5054443227 @default.
- W2120676861 creator A5072011188 @default.
- W2120676861 creator A5089938826 @default.
- W2120676861 date "2015-05-27" @default.
- W2120676861 modified "2023-10-10" @default.
- W2120676861 title "Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?" @default.
- W2120676861 cites W1544749943 @default.
- W2120676861 cites W1605523334 @default.
- W2120676861 cites W1937858809 @default.
- W2120676861 cites W1975498530 @default.
- W2120676861 cites W2000269004 @default.
- W2120676861 cites W2007679672 @default.
- W2120676861 cites W2040512792 @default.
- W2120676861 cites W2095670595 @default.
- W2120676861 cites W2096491867 @default.
- W2120676861 cites W2096738564 @default.
- W2120676861 cites W2096949802 @default.
- W2120676861 cites W2100085165 @default.
- W2120676861 cites W2100826058 @default.
- W2120676861 cites W2101719282 @default.
- W2120676861 cites W2102620699 @default.
- W2120676861 cites W2109176076 @default.
- W2120676861 cites W2111495238 @default.
- W2120676861 cites W2112262310 @default.
- W2120676861 cites W2119642155 @default.
- W2120676861 cites W2120627364 @default.
- W2120676861 cites W2127152525 @default.
- W2120676861 cites W2133667885 @default.
- W2120676861 cites W2137209705 @default.
- W2120676861 cites W2137347873 @default.
- W2120676861 cites W2137831643 @default.
- W2120676861 cites W2139726760 @default.
- W2120676861 cites W2140103603 @default.
- W2120676861 cites W2141546964 @default.
- W2120676861 cites W2145354914 @default.
- W2120676861 cites W2151082560 @default.
- W2120676861 cites W2154071455 @default.
- W2120676861 cites W2158679766 @default.
- W2120676861 cites W2159967578 @default.
- W2120676861 cites W2160088281 @default.
- W2120676861 cites W2165819904 @default.
- W2120676861 cites W2166199281 @default.
- W2120676861 cites W2167188058 @default.
- W2120676861 cites W2168083201 @default.
- W2120676861 cites W2169961966 @default.
- W2120676861 cites W2170241131 @default.
- W2120676861 cites W2219978888 @default.
- W2120676861 doi "https://doi.org/10.1634/theoncologist.2015-0002" @default.
- W2120676861 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4492241" @default.
- W2120676861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26018662" @default.
- W2120676861 hasPublicationYear "2015" @default.
- W2120676861 type Work @default.
- W2120676861 sameAs 2120676861 @default.
- W2120676861 citedByCount "46" @default.
- W2120676861 countsByYear W21206768612015 @default.
- W2120676861 countsByYear W21206768612016 @default.
- W2120676861 countsByYear W21206768612017 @default.
- W2120676861 countsByYear W21206768612018 @default.
- W2120676861 countsByYear W21206768612019 @default.
- W2120676861 countsByYear W21206768612020 @default.
- W2120676861 countsByYear W21206768612021 @default.
- W2120676861 countsByYear W21206768612022 @default.
- W2120676861 countsByYear W21206768612023 @default.
- W2120676861 crossrefType "journal-article" @default.
- W2120676861 hasAuthorship W2120676861A5008925729 @default.
- W2120676861 hasAuthorship W2120676861A5009976972 @default.
- W2120676861 hasAuthorship W2120676861A5023227998 @default.
- W2120676861 hasAuthorship W2120676861A5037725332 @default.
- W2120676861 hasAuthorship W2120676861A5054443227 @default.
- W2120676861 hasAuthorship W2120676861A5072011188 @default.
- W2120676861 hasAuthorship W2120676861A5089938826 @default.
- W2120676861 hasBestOaLocation W21206768611 @default.
- W2120676861 hasConcept C121608353 @default.
- W2120676861 hasConcept C126322002 @default.
- W2120676861 hasConcept C143998085 @default.
- W2120676861 hasConcept C156957248 @default.
- W2120676861 hasConcept C2775930923 @default.
- W2120676861 hasConcept C2780739268 @default.
- W2120676861 hasConcept C3019894029 @default.
- W2120676861 hasConcept C44249647 @default.
- W2120676861 hasConcept C530470458 @default.
- W2120676861 hasConcept C71924100 @default.
- W2120676861 hasConceptScore W2120676861C121608353 @default.
- W2120676861 hasConceptScore W2120676861C126322002 @default.
- W2120676861 hasConceptScore W2120676861C143998085 @default.
- W2120676861 hasConceptScore W2120676861C156957248 @default.
- W2120676861 hasConceptScore W2120676861C2775930923 @default.
- W2120676861 hasConceptScore W2120676861C2780739268 @default.
- W2120676861 hasConceptScore W2120676861C3019894029 @default.
- W2120676861 hasConceptScore W2120676861C44249647 @default.
- W2120676861 hasConceptScore W2120676861C530470458 @default.
- W2120676861 hasConceptScore W2120676861C71924100 @default.